Moneycontrol PRO
UPCOMING EVENT:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation

Subscribe to Ami Organics: Hem Securities

Hem Securities has come out with its report on Ami Organics. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 31, 2021.

September 01, 2021 / 02:48 PM IST
  • bselive
  • nselive
Todays L/H

Hem Securities IPO report on Ami Organics

Ami Organics has an experience of over 15 years of developing, manufacturing and commercialising advanced pharma intermediates used for manufacturing API and NCE in India and overseas. Company have developed and commercialised over 450 Pharma Intermediates across 17 key therapeutic areas since inception and NCE, which are being supplied to over 150 customers in India and 25 countries overseas. Some of the key therapeutic areas catered to by company include anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, antidepressant and anti-coagulant.

Valuation and Outlook

Additionally, recent acquisition of GOL’s business will also be growth driver of company going forward. Looking after all above we recommend “Subscribe” on issue.

For all IPO stories, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark